[Expression of SIPA1 in colorectal cancer and its impact on its biological behavior].

Q3 Medicine
N Z Wang, L Zhang, J Chen, H Chen, R C Wang, C H Lu, Y F Ji
{"title":"[Expression of SIPA1 in colorectal cancer and its impact on its biological behavior].","authors":"N Z Wang, L Zhang, J Chen, H Chen, R C Wang, C H Lu, Y F Ji","doi":"10.3760/cma.j.cn112152-20240812-00338","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> To investigate the expression of signal-induced proliferation-associated 1 (SIPA1) in colorectal cancer tissues and its relationship with patient prognosis. To explore the effects of SIPA1 on proliferation and migration abilities, as well as the possible molecular mechanisms. <b>Methods:</b> Using The Cancer Genome Atlas (TCGA) database to analyze the differential expression of SIPA1 and conduct survival analysis. Then, plotting receiver operating characteristic curve (ROC) and prognosis calibration curve analysis to assess the predictive capability and accuracy of SIPA1 for patient prognosis. Subsequently, verifying the expression levels of SIPA1 in tumor tissues and adjacent normal tissues using immunohistochemistry (IHC) and western blot (WB) assays(from March 1, 2023, to May 1, 2024, pathological specimens of five colorectal cancer patients were selected from the tissue bank of affiliated hospital of Nantong University. tissue microarrays were constructed using both cancerous tissues and adjacent normal tissues), and exploring the correlation between SIPA1 and clinical pathological parameters. Next, establishing SIPA1 stable knockdown cell lines in colorectal cancer cell lines DLD1 and HCT116, and assessing the biological behavior changes of tumor cells after SIPA1 knockdown through cell proliferation, invasion, and migration experiments. Validating the impact of SIPA1 on colorectal cancer cell proliferation <i>in vivo</i> through subcutaneous xenograft experiments in nude mice. Exploring the potential pro-tumor mechanisms of SIPA1 through pathway enrichment analysis, and confirming these using WB experiments. The proliferation, invasion and migration of tumor cells were detected after adding PI3K activator. Lastly, conducting correlation analysis between SIPA1 and immune checkpoint, as well as the association with immune cells in the tumor microenvironment. <b>Results:</b> Differential analysis showed that mRNA expression of SIPA1 in colorectal cancer tissues was significantly higher than that in adjacent normal tissues (<i>P</i><0.05). Prognostic analysis indicated that patients with high expression of SIPA1 had poor overall survival (<i>P</i><0.001), and the expression level of SIPA1was correlated with lymph node invasion (<i>P</i><0.001) and N stage (<i>P</i><0.05). ROC curve and prognosis calibration curve suggest that SIPA1 can effectively predict five-year survival rate of patients (AUC=0.7), and the predictive performance of the model is relatively accurate (<i>P</i><0.001). WB experiments showed a significant increase in the expression level of SIPA1 protein in colorectal cancer specimens (<i>P</i><0.001). Immunohistochemistry results indicated higher staining scores of SIPA1 in tumor tissues. <i>In vitro</i> experiments demonstrated that SIPA1 knockdown significantly inhibited the proliferation, invasion, and migration capabilities of colorectal cancer cells. In DLD1 and HCT116 cells, the SIPA1-knockdown group exhibited significantly lower absorbance compared to the control group (0.89±0.01 vs. 1.57±0.02 and 0.72±0.01 vs. 1.31±0.03, respectively, both <i>P</i><0.001). The SIPA1-knockdown group also demonstrated a reduced number of migrated cells relative to the control group (197.93±16.64 vs. 518.48±29.15 and 171.83±12.49 vs. 446.00±21.81, respectively, both <i>P</i><0.001). Furthermore, the cell wound-healing rate was significantly lower in the SIPA1-knockdown group than that in the control group [(0.32±0.01)% vs. (0.61±0.01)% and (0.28±0.01)% vs. (0.75±0.01)%, respectively, both <i>P</i><0.001]. <i>In vivo</i> animal experiments suggested that SIPA1 knockdown could inhibit tumor growth [(460.35±57.47) mm³ <i>vs</i> (1 177.55±208.24)mm³, (0.76±0.11)g <i>vs</i> (1.43±0.08)g, <i>P</i><0.05]. Pathway enrichment analysis revealed significant enrichment of the receptor tyrosine kinase signaling pathway, and SIPA1 knockdown could inhibit the activation of the phosphatidylinositide 3-kinases (PI3K)/protein kinase B (PKB)/glycogen synthase kinase-3β (GSK3β) signaling pathway. The PI3K activator reversed the inhibitory effect of SIPA1 silencing on tumor cell proliferation, invasion and migration. Correlation analysis indicated that high expression of SIPA1 was associated with immune checkpoints and various immunosuppressive cells (all <i>P</i><0.05). <b>Conclusions:</b> SIPA1 is highly expressed in colorectal cancer and associated with poor prognosis. SIPA1 may affect the proliferation and migration abilities of tumor cells by regulating the PI3K/AKT/GSK3β signaling pathway.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"657-668"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肿瘤杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112152-20240812-00338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To investigate the expression of signal-induced proliferation-associated 1 (SIPA1) in colorectal cancer tissues and its relationship with patient prognosis. To explore the effects of SIPA1 on proliferation and migration abilities, as well as the possible molecular mechanisms. Methods: Using The Cancer Genome Atlas (TCGA) database to analyze the differential expression of SIPA1 and conduct survival analysis. Then, plotting receiver operating characteristic curve (ROC) and prognosis calibration curve analysis to assess the predictive capability and accuracy of SIPA1 for patient prognosis. Subsequently, verifying the expression levels of SIPA1 in tumor tissues and adjacent normal tissues using immunohistochemistry (IHC) and western blot (WB) assays(from March 1, 2023, to May 1, 2024, pathological specimens of five colorectal cancer patients were selected from the tissue bank of affiliated hospital of Nantong University. tissue microarrays were constructed using both cancerous tissues and adjacent normal tissues), and exploring the correlation between SIPA1 and clinical pathological parameters. Next, establishing SIPA1 stable knockdown cell lines in colorectal cancer cell lines DLD1 and HCT116, and assessing the biological behavior changes of tumor cells after SIPA1 knockdown through cell proliferation, invasion, and migration experiments. Validating the impact of SIPA1 on colorectal cancer cell proliferation in vivo through subcutaneous xenograft experiments in nude mice. Exploring the potential pro-tumor mechanisms of SIPA1 through pathway enrichment analysis, and confirming these using WB experiments. The proliferation, invasion and migration of tumor cells were detected after adding PI3K activator. Lastly, conducting correlation analysis between SIPA1 and immune checkpoint, as well as the association with immune cells in the tumor microenvironment. Results: Differential analysis showed that mRNA expression of SIPA1 in colorectal cancer tissues was significantly higher than that in adjacent normal tissues (P<0.05). Prognostic analysis indicated that patients with high expression of SIPA1 had poor overall survival (P<0.001), and the expression level of SIPA1was correlated with lymph node invasion (P<0.001) and N stage (P<0.05). ROC curve and prognosis calibration curve suggest that SIPA1 can effectively predict five-year survival rate of patients (AUC=0.7), and the predictive performance of the model is relatively accurate (P<0.001). WB experiments showed a significant increase in the expression level of SIPA1 protein in colorectal cancer specimens (P<0.001). Immunohistochemistry results indicated higher staining scores of SIPA1 in tumor tissues. In vitro experiments demonstrated that SIPA1 knockdown significantly inhibited the proliferation, invasion, and migration capabilities of colorectal cancer cells. In DLD1 and HCT116 cells, the SIPA1-knockdown group exhibited significantly lower absorbance compared to the control group (0.89±0.01 vs. 1.57±0.02 and 0.72±0.01 vs. 1.31±0.03, respectively, both P<0.001). The SIPA1-knockdown group also demonstrated a reduced number of migrated cells relative to the control group (197.93±16.64 vs. 518.48±29.15 and 171.83±12.49 vs. 446.00±21.81, respectively, both P<0.001). Furthermore, the cell wound-healing rate was significantly lower in the SIPA1-knockdown group than that in the control group [(0.32±0.01)% vs. (0.61±0.01)% and (0.28±0.01)% vs. (0.75±0.01)%, respectively, both P<0.001]. In vivo animal experiments suggested that SIPA1 knockdown could inhibit tumor growth [(460.35±57.47) mm³ vs (1 177.55±208.24)mm³, (0.76±0.11)g vs (1.43±0.08)g, P<0.05]. Pathway enrichment analysis revealed significant enrichment of the receptor tyrosine kinase signaling pathway, and SIPA1 knockdown could inhibit the activation of the phosphatidylinositide 3-kinases (PI3K)/protein kinase B (PKB)/glycogen synthase kinase-3β (GSK3β) signaling pathway. The PI3K activator reversed the inhibitory effect of SIPA1 silencing on tumor cell proliferation, invasion and migration. Correlation analysis indicated that high expression of SIPA1 was associated with immune checkpoints and various immunosuppressive cells (all P<0.05). Conclusions: SIPA1 is highly expressed in colorectal cancer and associated with poor prognosis. SIPA1 may affect the proliferation and migration abilities of tumor cells by regulating the PI3K/AKT/GSK3β signaling pathway.

SIPA1在结直肠癌中的表达及其对生物学行为的影响
目的:探讨信号诱导增殖相关1 (signal-induced proliferation-associated 1, SIPA1)在结直肠癌组织中的表达及其与预后的关系。探讨SIPA1对细胞增殖和迁移能力的影响及其可能的分子机制。方法:利用癌症基因组图谱(Cancer Genome Atlas, TCGA)数据库分析SIPA1的差异表达并进行生存分析。然后绘制受试者工作特征曲线(ROC)和预后校准曲线分析,评估SIPA1对患者预后的预测能力和准确性。随后,采用免疫组化(IHC)和免疫印迹(WB)方法验证SIPA1在肿瘤组织和邻近正常组织中的表达水平(2023年3月1日至2024年5月1日,从南通大学附属医院组织库中选取5例结直肠癌患者的病理标本)。利用癌组织和邻近正常组织构建组织微阵列),探讨SIPA1与临床病理参数的相关性。接下来,在大肠癌细胞系DLD1和HCT116中建立SIPA1稳定敲低细胞系,通过细胞增殖、侵袭和迁移实验,评估SIPA1敲低后肿瘤细胞的生物学行为变化。通过裸鼠皮下异种移植实验验证SIPA1对体内结直肠癌细胞增殖的影响。通过通路富集分析,探索SIPA1潜在的促肿瘤机制,并通过WB实验进行证实。加入PI3K激活剂后检测肿瘤细胞的增殖、侵袭和迁移。最后,分析SIPA1与免疫检查点的相关性,以及与肿瘤微环境中免疫细胞的相关性。结果:差异分析显示SIPA1 mRNA在结直肠癌组织中的表达明显高于癌旁正常组织(P<0.05)。预后分析显示SIPA1高表达患者总生存期较差(P<0.001),且SIPA1表达水平与淋巴结浸润(P<0.001)、N分期(P<0.05)相关。ROC曲线和预后校准曲线显示,SIPA1能有效预测患者5年生存率(AUC=0.7),模型预测性能较为准确(P<0.001)。WB实验显示SIPA1蛋白在结直肠癌标本中的表达水平显著升高(P<0.001)。免疫组化结果显示肿瘤组织中SIPA1的染色分数较高。体外实验表明,SIPA1敲低可显著抑制结直肠癌细胞的增殖、侵袭和迁移能力。在DLD1和HCT116细胞中,sipa1敲低组的吸光度明显低于对照组(分别为0.89±0.01比1.57±0.02和0.72±0.01比1.31±0.03,P均<0.001)。sipa1敲低组与对照组相比,迁移细胞数量减少(分别为197.93±16.64 vs. 518.48±29.15和171.83±12.49 vs. 446.00±21.81,P均<0.001)。sipa1敲低组细胞创面愈合率显著低于对照组[分别为(0.32±0.01)%比(0.61±0.01)%和(0.28±0.01)%比(0.75±0.01)%,P均<0.001]。体内动物实验表明,SIPA1敲低可抑制肿瘤生长[(460.35±57.47)mm³vs(1 177.55±208.24)mm³,(0.76±0.11)g vs(1.43±0.08)g, P<0.05]。途径富集分析显示,受体酪氨酸激酶信号通路显著富集,SIPA1敲低可抑制磷脂酰亚脂3激酶(PI3K)/蛋白激酶B (PKB)/糖原合成酶激酶3β (GSK3β)信号通路的激活。PI3K激活剂逆转了SIPA1沉默对肿瘤细胞增殖、侵袭和迁移的抑制作用。相关分析显示SIPA1高表达与免疫检查点及多种免疫抑制细胞相关(均P<0.05)。结论:SIPA1在结直肠癌中高表达,且与预后不良相关。SIPA1可能通过调控PI3K/AKT/GSK3β信号通路影响肿瘤细胞的增殖和迁移能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
中华肿瘤杂志
中华肿瘤杂志 Medicine-Medicine (all)
CiteScore
1.40
自引率
0.00%
发文量
10433
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信